
Natco Pharma net jumps to ₹320 crore
The Hindu
HYDERABAD
Natco Pharma has posted a consolidated net profit of ₹320 crore for the quarter ended June, a manifold increase from ₹75 crore in the year earlier period.
The net profit came as the total revenue rose 115% to ₹918.9 crore (₹427.3 crore). Export sales of Lenalidomide product, which is indicated in the treatment of certain cancer, to the U.S. was a major contributor to the revenue and profitability during the quarter. Pharma domestic formulations business remained steady, the company said.
A sharp rise in formulation exports to ₹736.9 crore (₹145.4 crore) boosted the revenue even as contribution of API at ₹50.8 crore (₹61.6 crore) and formulations (domestic market) at ₹88.5 crore (₹200.6 crore) declined.
On the expense side, there was a one-time cost associated with retirement schemes and higher than usual research and development costs for product development, it said.
The company has declared an interim dividend of ₹3.50 per equity share (of ₹2 each) for 2022-23. The record date is fixed as August 22 and the interim dividend will be paid from August 30.

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












